Abstract
The therapeutic potential of medical cannabis to treat a variety of conditions is becoming increasingly recognised. Globally, a large number of countries have now legalised cannabis for medical uses and a substantial number of patients are able to access their medications. Yet in the UK, where medical cannabis was legalised in November 2018, only a handful of NHS prescriptions have been written, meaning that most patients are unable to access the medicine. Reasons for this are manyfold and include the perceived lack of clinical evidence due to the challenges of studying medical cannabis through randomised controlled trials. In order to develop the current evidence base, the importance of incorporating real-world data (RWD) to assess the effectiveness and efficacy of medical cannabis has gradually become recognised. The current paper provides a detailed outline of Project Twenty21 (T21), the UK’s first medical cannabis registry, launched in August 2020. We provide the rationale for T21 and describe the methodology before reporting the characteristics of the ‘first patients’ enrolled in the registry. We describe the health status of all patients enrolled into the project during its first 7 months of operation and the sociodemographic characteristics and primary presenting conditions for these patients, as well as details of the medical cannabis prescribed to these individuals. By 12th March 2021, 678 people had been enrolled into T21; the majority (64%) were male and their average age was 38.7 years (range = 18–80). The most commonly reported primary conditions were chronic pain (55.6%) and anxiety disorders (32.0%) and they reported high levels of multi-morbidity, including high rates of insomnia and depression. We also present preliminary evidence from 75 patients followed up after 3 months indicating that receipt of legal, prescribed cannabis was associated with a significant increase in self-reported health, assessed using the visual analogue scale of the EQ-5D-5L (Cohen’s d = .77, 95% CI = .51–1.03). Our initial findings complement reports from other large-scale databases globally, indicating that the current RWD is building up a pattern of evidence. With many clinicians demanding better and faster evidence to inform their decisions around prescribing medical cannabis, the current and future results of T21 will expand the existing evidence base on the effectiveness of cannabis-based medical products (CBMPs).
Similar content being viewed by others
References
BFarm (2020) Federal Institute for Drugs and Medical Devices. https://www.bfarm.de/DE/Bundesopiumstelle/Cannabis/Cannabisagentur/_node.html [accessed 15/03/2021]
Buysee DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213
Cleeland C (1991) Brief Pain Inventory. Handbook of Pain Assessment. New York: The Guilford Press. pp. 378-382
Conybeare D, Behar E, Solomon A, Newman MG, Borkovec TD (2012) The PTSD Checklist-Civilian Version: reliability, validity, and factor structure in a nonclinical sample. J Clin Psychol 68(6):699–713. https://doi.org/10.1002/jclp.21845
Couch D (2020) Left behind: the scale of illegal cannabis use for medicinal intent in the UK. https://www.thecmcuk.org/left-behind-the-scale-of-illegal-cannabis-use-for-medicinal-intent-in-the-uk [accessed 15/03/2021]
Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B (2018) Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ (United Kingdom) 27(1):7–22. https://doi.org/10.1002/hec.3564
FDA Framework for FDA’s Real-World Evidence Program (2018) FDA Framew. December. www.fda.gov. [accessed 15/03/2021]
Gossop M, Darke S, Griffiths P et al (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90(5):607–614. https://doi.org/10.1046/j.1360-0443.1995.9056072.x
Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E (2016) The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain 32
Health Canada (2015) The Research Institute of the McGill University Health Centre. https://registrecannabisquebec.com/en [accessed 15/03/2021]
Jansen MF, Bonsel GJ, Luo N (2018) Is EQ-5D-5L better than EQ-5D-5L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics 36(6):675–697
Jordan P, Shedden-Mora MC, Löwe B (2017) Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. PLoS ONE 12(8):1–14. https://doi.org/10.1371/journal.pone.0182162
Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS (2004) Validity of the Brief Pain Inventory for use in documenting. Clin J Pain 20(5):309–318
Mahabir VK, Merchant JJ, Smith C, Garibaldi A (2020) Medical cannabis use in the United States: a retrospective database study. J Cannabis Res 2:32. https://doi.org/10.1186/s42238-020-00038-w
Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T (2014) Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 14(1):1–10. https://doi.org/10.1186/1471-2377-14-58
Minnesota database (2020) The Minnesota Department of Health. https://www.health.state.mn.us/people/cannabis/docs/about/quarupdates/oct2020.pdf [accessed 15/03/2021]
National Institute for Heath and Care Excellence (NICE) Cannabis-based medicinal products. NICE Guidelines [NG144]. Published: November 11, 2019. https://www.nice.org.uk/guidance/ng144 [accessed 15/03/2021]
Nutt D (2019) Why medical cannabis is still out of patients’ reach-an essay by David Nutt. BMJ 365. https://doi.org/10.1136/bmj.l1903
Nutt D, Bazire S, Phillips LD, Schlag AK (2020) So near yet so far: why won’t the UK prescribe medical cannabis? BMJ Open 10:e038687. https://doi.org/10.1136/bmjopen-2020-038687
Pascual (2020) Applications open to supply France with free medical cannabis via pilot program. Marijuana Business Daily. Available at: https://mjbizdaily.com/applications-open-to-supply-france-with-free-medical-cannabis/?mc_cid=aa2a155788&mc_eid=cf4b1ce754. Accessed 20 Apr 2021
Rancans E, Trapencieris M, Ivanovs R, Vrublevska J (2018) Validity of the PHQ-9 and PHQ-2 to screen for depression in nationwide primary care population in Latvia. Ann Gen Psychiatry 17(1):1–8. https://doi.org/10.1186/s12991-018-0203-5
Salazar CA, Tomko RL, Akbar SA, Squeglia LM, Mcclure EA (2019) Medical cannabis use among adults in the southeastern United States. Cannabis 2(1):53–65
Schlag A (2020) Regimes of medical cannabis: what lessons can be learned for the UK? Med Cannabis Cannabinoids 3:76–83
Schlag AK, Baldwin DS, Barnes M, Bazire S, Coathup R, Curran HV, McShane R, Phillips LD, Singh I, Nutt DJ (2020) Medical cannabis in the UK: from principle to practice. J Psychopharmacol 34(9):931–937. https://doi.org/10.1177/0269881120926677
Schlienz NJ, Scalsky R, Martin EL, Jackson H, Munson J, Strickland JC, Bonn-Miller MO, Loflin M, Vandrey R (2020) A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health. Cannabis Cannabinoid Res. https://doi.org/10.1089/can.2019.0096
Scott W, McCracken LM (2015) Patients’ impression of change following treatment for chronic pain: global, specific, a single dimension, or many? J Pain 16(6):518–526. https://doi.org/10.1016/j.jpain
Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1:131–138. https://doi.org/10.1089/can.2016.0007
Storch EA, Murphy TK, Geffken GR et al (2005) Reliability and validity of the Yale Global Tic Severity Scale. Psychol Assess 17(4):486–491. https://doi.org/10.1037/1040-3590.17.4.486
United Patients’ Alliance (UPA) (2018) UPA Patients’ Survey 2018. [accessed 15/03/2021]
Acknowledgements
We thank the licenced producers of T21: Khiron Life Sciences, Bod Australia Ltd., Cellen Therapeutics, Lyphe Group, JMCC Group and Alta-Flora.
Funding
Drug Science.
Author information
Authors and Affiliations
Contributions
CS developed the initial draft. ML conducted and wrote up the data analysis. AKS and DJN wrote the introduction and sections on real-world evidence, as well as sections on other databases. All authors revised the manuscript and agreed on the final draft.
Corresponding author
Ethics declarations
Conflict of interest
CS was clinical director of T21 until September 2020. AKS is head of research at the charity Drug Science. ML is head of data at Drug Science. DJN is chair of Drug Science.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article belongs to a Special Issue on Cannabis and Cannabinoids S.
Rights and permissions
About this article
Cite this article
Sakal, C., Lynskey, M., Schlag, A.K. et al. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. Psychopharmacology 239, 1147–1155 (2022). https://doi.org/10.1007/s00213-021-05855-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-021-05855-2